Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 394206, 7 pages
http://dx.doi.org/10.1155/2014/394206
Research Article

TNF-α and Microalbuminuria in Patients with Type 2 Diabetes Mellitus

1Department of Nephrology, “Hippokratio” General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 546 42 Thessaloniki, Greece
21st Propedeutic Department of Internal Medicine, Diabetes Center, “AHEPA” General Hospital, Aristotle University of Thessaloniki, 546 36 Thessaloniki, Greece

Received 5 July 2014; Revised 11 September 2014; Accepted 19 September 2014; Published 22 December 2014

Academic Editor: Salwa Ibrahim

Copyright © 2014 I.-Th. Lampropoulou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Molitch, R. A. DeFronzo, M. J. Franz et al., “Nephropathy in diabetes,” Diabetes Care, vol. 27, supplement 1, pp. s79–s83, 2004. View at Publisher · View at Google Scholar
  2. KDOQI, “Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, supplement 2, pp. S12–S154, 2007. View at Google Scholar
  3. C. W. Heilig, L. A. Concepcion, B. L. Riser et al., “Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype,” The Journal of Clinical Investigation, vol. 96, no. 4, pp. 1802–1814, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Cooper, “Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy,” Diabetologia, vol. 44, no. 11, pp. 1957–1972, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. E. D. Schleicher and C. Weigert, “Role of the hexosamine biosynthetic pathway in diabetic nephropathy,” Kidney International, Supplement, vol. 58, no. 77, pp. S13–S18, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S.-Y. Goh and M. E. Cooper, “The role of advanced glycation end products in progression and complications of diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 4, pp. 1143–1152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Makita, S. Radoff, E. J. Rayfield et al., “Advanced glycosylation end products in patients with diabetic nephropathy,” The New England Journal of Medicine, vol. 325, no. 12, pp. 836–842, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. S. T. Crowley, M. Brownlee, D. Edelstein et al., “Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells,” Diabetes, vol. 40, no. 5, pp. 540–547, 1991. View at Publisher · View at Google Scholar · View at Scopus
  10. S.-I. Yamagishi and T. Matsui, “Advanced glycation end products, oxidative stress and diabetic nephropathy,” Oxidative Medicine and Cellular Longevity, vol. 3, no. 2, pp. 101–108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Wautier and P. J. Guillausseau, “Advanced glycation end products, their receptors and diabetic angiopathy,” Diabetes and Metabolism, vol. 27, no. 5, pp. 535–542, 2001. View at Google Scholar · View at Scopus
  12. H. Makino, M. Haneda, T. Babazono et al., “Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes,” Diabetes Care, vol. 30, no. 6, pp. 1577–1578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. Navarro-González, C. Mora-Fernández, M. M. de Fuentes, and J. García-Pérez, “Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 6, pp. 327–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Rivero, C. Mora, M. Muros, J. García, H. Herrera, and J. F. Navarro-González, “Pathogenic perspectives for the role of inflammation in diabetic nephropathy,” Clinical Science, vol. 116, no. 6, pp. 479–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. F. Navarro-González and C. Mora-Fernández, “The role of inflammatory cytokines in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 433–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. Navarro, C. Mora, M. Gómez, M. Muros, C. López-Aguilar, and J. García, “Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 919–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nakamura, M. Fukui, I. Ebihara et al., “mRNA expression of growth factors in glomeruli from diabetic rats,” Diabetes, vol. 42, no. 3, pp. 450–456, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. J. F. Navarro, F. J. Milena, C. Mora et al., “Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition,” Kidney International, vol. 68, no. 99, pp. S-98–S-102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. F. Navarro, C. Mora, M. Macía, and J. García, “Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 53–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Lin, F. B. Hu, C. Mantzoros, and G. C. Curhan, “Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes,” Diabetologia, vol. 53, no. 2, pp. 263–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. K. L. Ma, Y. Zhang, J. Liu et al., “Establishment of an inflamed animal model of diabetic nephropathy,” International Journal of Biological Sciences, vol. 10, no. 2, pp. 149–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Sassy-Prigent, D. Heudes, C. Mandet et al., “Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats,” Diabetes, vol. 49, no. 3, pp. 466–475, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Choudhary and R. S. Ahlawat, “Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria,” Iranian Journal of Kidney Diseases, vol. 2, no. 2, pp. 72–79, 2008. View at Google Scholar · View at Scopus
  26. M. A. Niewczas, L. H. Ficociello, A. C. Johnson et al., “Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 62–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. L. Klein, S. J. Hunter, A. J. Jenkins et al., “Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort,” Diabetes Care, vol. 26, no. 5, pp. 1439–1448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Corti, F. D'Ambrosio, M. Marino, S. Merli, and G. Cassani, “Identification of differentially glycosylated forms of the soluble p75 tumor necrosis factor (TNF) receptor in human urine,” European Cytokine Network, vol. 6, no. 1, pp. 29–35, 1995. View at Google Scholar · View at Scopus
  29. W. Bao, D. Min, S. M. Twigg et al., “Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: Possible role in diabetic complications,” American Journal of Physiology—Cell Physiology, vol. 299, no. 5, pp. C1212–C1219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Mastej and R. Adamiec, “Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy,” Acta Diabetologica, vol. 45, no. 3, pp. 183–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. F. Navarro-González, A. Jarque, M. Muros, C. Mora, and J. García, “Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 165–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Moriwaki, T. Yamamoto, Y. Shibutani et al., “Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy,” Metabolism: Clinical and Experimental, vol. 52, no. 5, pp. 605–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Wu, Y. Ding, C. Zhu et al., “Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes,” Experimental and Therapeutic Medicine, vol. 6, no. 6, pp. 1482–1488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kalantarinia, A. S. Awad, and H. M. Siragy, “Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats,” Kidney International, vol. 64, no. 4, pp. 1208–1213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Omote, T. Gohda, M. Murakoshi et al., “Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice,” American Journal of Physiology: Renal Physiology, vol. 306, no. 11, pp. F1335–F1347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Wang, M. Wei, M. Wang et al., “Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice,” Inflammation, 2014. View at Publisher · View at Google Scholar
  37. J. F. Navarro-González, C. Mora-Fernández, M. M. de Fuentes et al., “Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial,” Journal of the American Society of Nephrology, 2014. View at Publisher · View at Google Scholar